Mirati Therapeutics price target raised to $82 from $58 at JMP Securities

JMP Securities raised the firm’s price target on Mirati Therapeutics (MRTX) to $82 from $58 and keeps an Outperform rating on the shares. Several updates led to a rally in Mirati shares, including the AdComm vote on a competitor’s KRASi determined that primary endpoint of CodeBreaK200 cannot reliably be interpreted, potentially leaving Mirati’s adagrasib as the sol option in 2L NSCLC, the analyst tells investors in a research note. In addition, Sanofi (SNY) is considering an acquisition of Mirati, according to Bloomberg, the analyst say.